Clearmind Biomedical, a pioneer in minimally invasive neurosurgical technologies, today announced that it has entered into an exclusive U.S. distribution partnership with Sutter Medical for its Neuroblade Multi-Function Neuro-Endoscope System. The Neuroblade, which has received 510(k) clearance, is designed to transform the management of complex neurosurgical conditions such as intracerebral hemorrhage (ICH), one of the most fatal and disabling forms of stroke.
ICH continues to represent a critical challenge in neurosurgery due to its limited treatment options and high rates of mortality and long-term disability. The Neuroblade system aims to address this unmet clinical need by offering neurosurgeons an integrated, minimally invasive solution for hemorrhage evacuation. The advanced platform combines multiple essential surgical functions—including visualization, illumination, irrigation, suction, coagulation, and powered debridement—into a single device. This integration not only enhances surgical precision and workflow efficiency but also minimizes the need for instrument exchanges, supporting safer and faster procedures with the potential to improve patient recovery outcomes.
“Clearmind’s mission has always been centered on advancing the treatment of hemorrhagic stroke by equipping surgeons with technology that helps patients not only survive but regain independence,” said J. Dustin Duckett, Vice President and General Manager, Americas at Clearmind Biomedical. “Through our collaboration with Sutter Medical, we are positioned to accelerate the adoption of the Neuroblade across top neurosurgical and stroke centers throughout the U.S., enabling clinicians to perform these critical procedures with greater confidence and efficiency.”
Under the terms of the agreement, Sutter Medical—globally recognized for its expertise in precision surgical tools such as non-stick bipolar forceps and radiofrequency systems—will serve as the exclusive distributor of the Neuroblade in the United States. Leveraging Sutter’s established commercial network and trusted relationships with neurosurgeons, the partnership will ensure broader access to this groundbreaking technology.
“We are thrilled to bring the Neuroblade into our U.S. portfolio,” said Brent Lacy, Vice President of Sutter Medical. “Its unique combination of minimally invasive access and integrated multi-functionality aligns with our goal of empowering neurosurgeons to enhance precision, streamline workflows, and achieve better patient outcomes.”
The Neuroblade will be showcased at the upcoming Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 11–15, 2025, at Booth #350.
